Astellas is currently pitching peak sales guidance of 300 billion yen ($2.2 billion) to 500 billion yen per year for Veozah, which could go a long way to ease the pain of patent losses to its ...

New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah ...

If you are missing out on a good night’s sleep due to vasomotor symptoms, talk to your doctor about solutions, including ...

Idiopathic intracranial hypertension (IIH) is a rare but important disease associated with significant morbidity. There is an expected rise in prevalence in line with the escalating global burden of ...